NEW YORK, June 20 - Luminex said Wednesday its board of directors has adopted a shareholders rights plan designed to prevent hostile takeover bids.

Luminex, an Austin, Texas-based developer of microarray bead technology, said that the decision to adopt the rights plan was not a reaction to any outside attempt to takeover the company.

"The adoption of the rights plan is merely a means of safeguarding against abusive takeover tactics and is not in response to any accumulation of shares or hostile takeover attempt,” Mark Chandler, Luminex’s CEO said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.